X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ophthalmology (8) 8
ranibizumab (8) 8
aflibercept (7) 7
humans (7) 7
vegf trap-eye (7) 7
life sciences & biomedicine (6) 6
macular degeneration (6) 6
science & technology (6) 6
vascular endothelial growth factor (6) 6
vascular endothelial growth factor a - antagonists & inhibitors (6) 6
bevacizumab (5) 5
recombinant fusion proteins - therapeutic use (5) 5
angiogenesis inhibitors - therapeutic use (4) 4
antibodies, monoclonal, humanized - therapeutic use (4) 4
diabetic macular edema (4) 4
eye diseases (4) 4
genetic structures (4) 4
intravitreal injections (4) 4
receptors, vascular endothelial growth factor - therapeutic use (4) 4
review (4) 4
angiogenesis (3) 3
diabetic retinopathy (3) 3
diabetic retinopathy - drug therapy (3) 3
drug therapy (3) 3
macular edema - drug therapy (3) 3
pegaptanib (3) 3
physiological aspects (3) 3
retinopathy (3) 3
vascular endothelial growth factor trap-eye (3) 3
age-related macular degeneration (2) 2
angiogenesis inhibitors - adverse effects (2) 2
animals (2) 2
anti-vascular endothelial growth factor (2) 2
anti-vascular endothelial growth factor agents (2) 2
choroidal neovascularization (2) 2
clinical trials (2) 2
clinical trials as topic (2) 2
comparative analysis (2) 2
da vinci (2) 2
laser (2) 2
macular degeneration - drug therapy (2) 2
medical research (2) 2
neovascular age-related macular degeneration (2) 2
neovascularization (2) 2
tomography, optical coherence (2) 2
visual acuity - drug effects (2) 2
visual acuity - physiology (2) 2
wet macular degeneration - drug therapy (2) 2
abridged index medicus (1) 1
acuity (1) 1
age (1) 1
age related macular degeneration (1) 1
aged (1) 1
agents (1) 1
amd (1) 1
angiogenesis inhibitors - administration & dosage (1) 1
angiogenesis inhibitors - economics (1) 1
anti-vascular (1) 1
anti-vascular endothelial growth factor trap-eye (1) 1
antibodies, monoclonal, humanized - administration & dosage (1) 1
antibodies, monoclonal, humanized - adverse effects (1) 1
antibodies, monoclonal, humanized - economics (1) 1
antivascular endothelial growth factor (1) 1
aptamers, nucleotide - therapeutic use (1) 1
bevasiranib (1) 1
care and treatment (1) 1
chemical compounds (1) 1
chemistry, medicinal (1) 1
choroidal neovascularization - drug therapy (1) 1
choroidal neovascularization - pathology (1) 1
colorectal cancer (1) 1
conbercept (1) 1
delivery of health care - standards (1) 1
delivery of health care - trends (1) 1
dexamethasone - therapeutic use (1) 1
diabetes (1) 1
diabetes mellitus (1) 1
diabetic (1) 1
diabetic macular oedema (1) 1
diabetic retinopathy - diagnosis (1) 1
diabetic retinopathy - physiopathology (1) 1
dme (1) 1
double-blind method (1) 1
drug design, development and therapy (1) 1
durability (1) 1
edema (1) 1
effectiveness (1) 1
endocrinology (1) 1
endothelial (1) 1
endothelial cells (1) 1
endothelial growth factors (1) 1
endothelium (1) 1
eye (1) 1
eylea (1) 1
factor (1) 1
female (1) 1
fluorescein angiography (1) 1
fusion proteins (1) 1
gastroenterology (1) 1
glucocorticoids - therapeutic use (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Drug design, development and therapy, ISSN 1177-8881, 08/2013, Volume 7, pp. 711 - 722
Background: Vascular endothelial growth factor (VEGF) is a naturally occurring glycoprotein in the body that acts as a growth factor for endothelial cells. It... 
AMD | Neovascularization | VEGF-Trap eye | Aflibercept | VEGF | VEGF inhibition | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Chemistry, Medicinal | Science & Technology | Antibodies, Monoclonal, Humanized - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Intravitreal Injections | Recombinant Fusion Proteins - pharmacology | Humans | Receptors, Vascular Endothelial Growth Factor - pharmacology | Recombinant Fusion Proteins - therapeutic use | Wet Macular Degeneration - physiopathology | Clinical Trials as Topic | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Receptors, Vascular Endothelial Growth Factor - administration & dosage | Animals | Wet Macular Degeneration - drug therapy | Choroidal Neovascularization - drug therapy | Choroidal Neovascularization - pathology | Ranibizumab | Recombinant Fusion Proteins - administration & dosage | Macular degeneration | Pharmaceutical research | Physiological aspects | Research | Drug therapy | Vascular endothelial growth factor | Medical research | Diabetic retinopathy | Retinopathy | Effectiveness | Diabetes mellitus | Clinical trials | Risk reduction | Durability | Retina | Visual acuity | Pharmacology | Glycoproteins | Permeability | Chemical compounds | Two phase | Endothelial cells | Vascularization | Acuity | Eye | Angiogenesis | Growth factors | Age | Index Medicus | aflibercept | neovascularization
Journal Article
Journal Article
Expert review of ophthalmology, ISSN 1746-9899, 10/2011, Volume 6, Issue 5, pp. 513 - 516
Journal Article
Biologics in therapy, ISSN 2190-9164, 05/2012, Volume 2, Issue 1, pp. 1 - 22
In the western hemisphere, age-related macular degeneration (AMD) is the leading cause of visual loss in the elderly. Currently approved therapies for AMD... 
Medicine & Public Health | Age-related macular degeneration | Vascular endothelial growth factor Trap-Eye | Rheumatology | Gastroenterology | Neovascular age-related macular degeneration | Infectious Diseases | Internal Medicine | Oncology | Antivascular endothelial growth factor | Aflibercept | Endocrinology
Journal Article
International journal of retina and vitreous, ISSN 2056-9920, 12/2016, Volume 2, Issue 1, pp. 3 - 3
In the last few years, monoclonal antibodies have revolutionized the treatment of retinal neovascular diseases. More recently, a different class of drugs,... 
Conbercept | Aflibercept | Fusion proteins | Ziv-aflibercept | Vascular endothelial growth factor (VEGF) | VEGF Trap Eye | Proteins | Medical research | Care and treatment | Colorectal cancer | Monoclonal antibodies | Medicine, Experimental | Ophthalmology | Retinal diseases | Vascular endothelial growth factor
Journal Article
Retina (Philadelphia, Pa.), ISSN 0275-004X, 04/2015, Volume 35, Issue 4, pp. 687 - 694
Journal Article
World journal of diabetes, ISSN 1948-9358, 2013, Volume 4, Issue 6, pp. 303 - 309
Diabetic retinopathy(DR)is the most common cause of visual loss among working age individuals.Diabetic macular edema(DME)is an important complication of DR... 
macular | Anti-vascular | EYLEA | edema | trap-eye | Vascular | Aflibercept | agents | retinopathy | endothelial | Diabetic | growth | factor | Diabetic retinopathy | Diabetic macular edema | Topic Highlight | Vascular endothelial growth factor trap-eye | Anti-vascular endothelial growth factor agents
Journal Article
Atención farmacéutica, ISSN 1139-7357, 05/2012, Volume 14, Issue 3, pp. 194 - 201
Journal Article
Oman journal of ophthalmology, ISSN 0974-620X, 10/2014, Volume 7, Issue 3, pp. 112 - 115
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.